HZNP Horizon Therapeutics
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
Company profile
Ticker
HZNP
Exchange
Website
CEO
Timothy P. Walbert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Horizon Pharma plc, HORIZON PHARMA, INC.
SEC CIK
Corporate docs
IRS number
272179987
HZNP stock data
()
News
Stocks That Hit 52-Week Highs On Wednesday
24 Feb 21
Why Horizon Therapeutics's Stock is Trading Higher Today
24 Feb 21
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
24 Feb 21
Recap: Horizon Therapeutics Q4 Earnings
24 Feb 21
Horizon Therapeutics Q4 Adj. EPS $1.28 Beats $1.05 Estimate, Sales $745.30M Beat $690.03M Estimate
24 Feb 21
Press releases
New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase
22 Feb 21
(VIE Alert) Johnson Fistel Investigates Proposed Sale of Viela Bio; Are Shareholders Getting a Fair Deal?
20 Feb 21
VIELA BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Viela Bio, Inc. - VIE
4 Feb 21
Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
4 Feb 21
Thinking about trading options or stock in Pfizer, Daqo New Energy, Horizon Therapeutics, Intel Corp, or G1 Therapeutics?
2 Feb 21
Investment data
Securities sold
Number of investors
Calendar
24 Feb 21
25 Feb 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 Feb 21 | Karnani Vikram | Ordinary Shares | Sell | Dispose S | No | Yes | 88.4502 | 645 | 57.05K | 104,165 |
| 22 Feb 21 | Karnani Vikram | Ordinary Shares | Sell | Dispose S | No | Yes | 87.083 | 7,713 | 671.67K | 104,810 |
| 22 Feb 21 | Konstantinovsky Irina | Ordinary Shares | Sell | Dispose S | No | Yes | 88.4986 | 474 | 41.95K | 81,677 |
| 22 Feb 21 | Konstantinovsky Irina | Ordinary Shares | Sell | Dispose S | No | Yes | 87.1055 | 5,224 | 455.04K | 82,151 |
| 21 Feb 21 | DesJardin Michael A. | Ordinary Shares | Payment of exercise | Dispose F | No | No | 88.87 | 1,082 | 96.16K | 103,290 |
| 21 Feb 21 | DesJardin Michael A. | Ordinary Shares | Option exercise | Aquire M | No | No | 0 | 2,182 | 0 | 104,372 |
| 21 Feb 21 | DesJardin Michael A. | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 2,182 | 0 | 0 |
| 21 Feb 21 | Daniel A. Camardo | Ordinary Shares | Payment of exercise | Dispose F | No | No | 88.87 | 576 | 51.19K | 45,800 |
| 21 Feb 21 | Daniel A. Camardo | Ordinary Shares | Option exercise | Aquire M | No | No | 0 | 1,300 | 0 | 46,376 |
| 21 Feb 21 | Daniel A. Camardo | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 1,300 | 0 | 0 |
Institutional ownership Q4 2020
88.9% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 464 |
| Opened positions | 110 |
| Closed positions | 69 |
| Increased positions | 165 |
| Reduced positions | 155 |
13F shares |
Current |
|---|---|
| Total value | 17.46B |
| Total shares | 196.32M |
| Total puts | 1.39M |
| Total calls | 3.9M |
| Total put/call ratio | 0.4 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 19.92M | $1.46B |
| BLK Blackrock | 14.21M | $1.04B |
| FMR | 13.25M | $969.49M |
| Avoro Capital Advisors | 9M | $658.35M |
| JHG Janus Henderson | 8.19M | $599.29M |
| Paulson & Co. | 7.99M | $584.57M |
| Renaissance Technologies | 6.8M | $497.34M |
| JPM JPMorgan Chase & Co. | 5.91M | $432.17M |
| William Blair Investment Management | 5.25M | $384.33M |
| STT State Street | 4.41M | $322.96M |
Financial report summary
?Competition
Aradigm • Cymabay Therapeutics • Acer Therapeutics • Aeglea BioTherapeutics • Translate BioManagement Discussion
- Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
- You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read the “Risk Factors” section of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
- Unless otherwise indicated or the context otherwise requires, references to “Horizon”, “we”, “us” and “our” refer to Horizon Therapeutics plc and its consolidated subsidiaries.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
advocacy, agenda, agile, Aid, aiding, Aisling, allyship, amplified, analyzed, Anchen, anesthesiologist, Annora, antagonism, antagonist, Aon, appointing, Appointment, attack, autoantibody, belatacept, bidding, Biden, Biovitrum, Boulder, Britain, broadcast, burnout, buy, Cadillac, calcineurin, Camardo, campaign, cap, capita, capped, caregiver, CEO, Certiorari, characterized, charity, Chase, Chicago, child, cholesterol, Citigroup, CJEU, club, coaching, college, Colorado, comment, constitutionality, copay, Copenhagen, courier, CPRA, Crain, Curzion, dcSSc, demographic, dendritic, Denmark, desensitization, destination, discrimination, dissolve, distancing, diverge, divergence, divergent, DPA, driven, embed, ENHANZE, enjoining, ensuing, epinephrine, ESRD, ethnicity, evidenced, exemplified, exocrine, expert, fiercely, finite, Forbion, FORTUNE, fostered, fusion, FVC, gender, glomerular, gradually, graduate, graft, Great, Halozyme, halt, harassment, harder, Helsinki, hematopoietic, Hetero, home, hosted, hyaluronidase, idiopathic, IFR, ILD, immunosuppressant, inappropriate, innate, inside, Insider, insulin, interstitial, intimidation, intravenously, IPF, Japanese, journey, JP, JPMorgan, Karin, land, learn, legislature, lifted, ligand, lipoprotein, loved, Lundbeckfond, lysophosphatidic, lysosomal, mail, main, meant, mechanistic, median, mediate, mediated, MFN, MHRA, Miravo, MMF, mofetil, Morgan, mortality, mRSS, myasthenia, mycophenolate, nationwide, native, neuromuscular, neutralize, NMOSD, Northern, onset, opposed, optica, Orchard, organizational, orientation, OTC, outlook, output, overactivation, overexpressed, overproduce, overproduction, overstimulation, pandemic, parallel, Parliament, pathogenic, pause, paused, pDC, perspective, pharmacodynamic, pharmacokinetic, physical, physically, plasma, plasmacytoid, play, pledge, poor, postponed, practitioner, precaution, presidential, prioritization, prioritize, prolonged, race, Racial, ransomware, rapid, rationale, recharge, RECIPE, recourse, referencing, reimplement, reimplemented, relapsed, religion, remanded, remote, remotely, renovation, rental, reopen, reopening, repositioned, RiverVest, Rodnan, room, salivary, SC, scholarship, school, Seattle, segregation, sequester, setback, sexual, shape, shelter, Sherman, Shield, shortly, shut, signatory, skillset, slot, Sobi, Society, spectrum, stable, Stanley, steroid, strain, student, subcutaneously, subset, suggest, suggested, supervisory, surface, surgical, Swedish, tackle, tariff, TCA, tear, Teiripic, teleconference, telemedicine, temporarily, tender, threat, throat, tie, timeframe, timeline, tough, trajectory, tuition, unavailable, unchanged, unpurchased, upheld, Uplizna, vaccine, vast, vehicle, venture, veteran, VIB, Viela, Viridian, virtual, visit, vital, voluntarily, volunteer, volunteering, Washington, welfare, workplace, worsening
Removed:
accretion, announce, antidrug, Aralez, Assent, bankrupt, BASF, Bishop, blend, blended, Blueprint, Bulletin, Carey, Chemie, Chile, Chimie, circumvent, citing, clarify, coated, compression, convincing, CSR, CU, dashboard, defaulting, deployed, derivative, disclosing, distributing, divested, Donald, effected, effectuated, endoscopic, England, erosive, expressly, FA, formulate, Halo, hybrid, illustrating, impressive, inconvenience, Innomar, instruct, intending, IPR, Journal, Lin, linear, linked, MassHealth, merged, Mexico, microspheronized, Minakem, mismatch, MRP, Mundipharma, negotiating, nerve, Nexium, ninety, Nonemployee, numbered, OCS, outlay, Pacific, persuasive, ph, Pharmacopeia, PMPRB, preceding, prevented, principle, proximal, PTAB, reach, reconcile, reinforce, renewing, retrospectively, Robert, Royal, Sanofi, Scandinavia, setting, sharing, shift, simplifying, sourced, Starnberg, strongly, supplying, Tianjin, Tianyao, today, transparent, trihydrate, twenty, typical, Uetikon, ulcer, unamortized, unaudited, unresponsive
Financial reports
10-K
2020 FY
Annual report
24 Feb 21
10-Q
2020 Q3
Quarterly report
2 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
26 Feb 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-K
2018 FY
Annual report
27 Feb 19
Current reports
8-K
Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020
24 Feb 21
8-K
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
1 Feb 21
8-K
Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding
11 Jan 21
8-K
Regulation FD Disclosure
22 Dec 20
8-K
Other Events
17 Dec 20
8-K
Results of Operations and Financial Condition
2 Nov 20
8-K
Other Events
9 Aug 20
8-K
Results of Operations and Financial Condition
5 Aug 20
8-K
Unregistered Sales of Equity Securities
23 Jun 20
8-K
Other Events
3 Jun 20
Registration and prospectus
SC TO-T/A
Third party tender offer statement (amended)
24 Feb 21
SC TO-T
Third party tender offer statement
12 Feb 21
SC TO-C
Information about tender offer
4 Feb 21
SC TO-C
Information about tender offer
1 Feb 21
SC TO-C
Information about tender offer
1 Feb 21
424B5
Prospectus supplement for primary offering
9 Aug 20
424B5
Prospectus supplement for primary offering
5 Aug 20
S-8
Registration of securities for employees
1 May 20
S-8
Registration of securities for employees
1 May 19
424B5
Prospectus supplement for primary offering
7 Mar 19
Proxies
DEFA14A
Additional proxy soliciting materials
18 Mar 20
DEF 14A
Definitive proxy
18 Mar 20
PRE 14A
Preliminary proxy
5 Mar 20
DEFA14A
Additional proxy soliciting materials
22 Apr 19
DEFA14A
Additional proxy soliciting materials
17 Apr 19
DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
8 Apr 19
PRE 14A
Preliminary proxy
22 Mar 19
DEF 14A
Definitive proxy
1 Apr 18
PRE 14A
Preliminary proxy
15 Mar 18
Other
CT ORDER
Confidential treatment order
14 Jul 20
CT ORDER
Confidential treatment order
14 Jul 20
CT ORDER
Confidential treatment order
14 Jul 20
CT ORDER
Confidential treatment order
14 Jul 20
CT ORDER
Confidential treatment order
14 Jul 20
CT ORDER
Confidential treatment order
14 Jul 20
CT ORDER
Confidential treatment order
9 Apr 20
CT ORDER
Confidential treatment order
9 Apr 20
CT ORDER
Confidential treatment order
9 Apr 20
CT ORDER
Confidential treatment order
17 Mar 20
Ownership
4
Horizon Therapeutics Public / Vikram Karnani ownership change
23 Feb 21
4
Horizon Therapeutics Public / Irina Konstantinovsky ownership change
23 Feb 21
4
Horizon Therapeutics Public / Michael A. DesJardin ownership change
23 Feb 21
4
Horizon Therapeutics Public / Daniel A. Camardo ownership change
23 Feb 21
4
Horizon Therapeutics Public / Jeff Kent ownership change
19 Feb 21
4
Horizon Therapeutics Public / Andy Pasternak ownership change
19 Feb 21
4
Horizon Therapeutics Public / Irina Konstantinovsky ownership change
19 Feb 21
4
Horizon Therapeutics Public / JEFFREY W SHERMAN ownership change
19 Feb 21
4
Horizon Therapeutics Public / Michael A. DesJardin ownership change
19 Feb 21
4
Horizon Therapeutics Public / Vikram Karnani ownership change
19 Feb 21
Patents
GRANT
Utility
Methods for storing cysteamine formulations and related methods of treatment
2 Feb 21
Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided.
GRANT
Utility
ADO-resistant cysteamine analogs and uses thereof
2 Feb 21
The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
APP
Utility
Methods for Treating Urea Cycle Disorders
6 Jan 21
Provided are methods of administering glycerol phenylbutyrate to a patient in need thereof, wherein said patient is also being treated with a CYP3A4 substrate having a narrow therapeutic index, midazolam or a pharmaceutically acceptable salt thereof, or celecoxib.
APP
Utility
Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs
6 Jan 21
The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
APP
Utility
Methods of Treating Urea Cycle Disorders
30 Dec 20
The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration.
Transcripts
2020 Q4
Earnings call transcript
24 Feb 21
2020 Q3
Earnings call transcript
2 Nov 20
2020 Q3
Earnings call transcript
2 Nov 20
2020 Q3
Earnings call transcript
2 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q4
Earnings call transcript
26 Feb 20
2019 Q3
Earnings call transcript
6 Nov 19
2019 Q2
Earnings call transcript
7 Aug 19
2019 Q1
Earnings call transcript
8 May 19
Reddit threads
Daily Discussion Thread - February 24th, 2021
24 Feb 21
Daily Discussion Thread - February 23rd, 2021
23 Feb 21
Daily Discussion Thread - February 22nd, 2021
22 Feb 21
Wall Street Week Ahead for the trading week beginning February 22nd, 2021
21 Feb 21
Assertio holdnings (ASRT) potential runner
15 Feb 21
Second Quarter Results: 6 months into the /r/investing underrated stock survey and the average return was 72% (37% as a portfolio)
9 Feb 21
ACTIVISION/BLIZZARD (ATVI): Today’s earnings call and some unique numbers make this is an interesting stock I wish I had jumped on.
4 Feb 21
Looking for new stocks to trade
3 Nov 20
Daily Discussion Thread - November 2nd, 2020
2 Nov 20
Daily Discussion Thread - October 30th, 2020
30 Oct 20